Please login to the form below

Not currently logged in
Email:
Password:

Biogen-Samsung's Enbrel biosimilar cleared for EU marketing

The companies plan to launch the treatment in the coming weeks
European Commission

The first biosimilar version of Pfizer/Amgen's big-selling tumour necrosis factor (TNF) inhibitor Enbrel has been given a green light in Europe.

The European Commission approved Samsung Bioepis' Benepali version of Enbrel (etanercept) for the treatment of adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis. The drug was previously known as SB4.

Enbrel is one of the top-selling drugs in the TNF inhibitor class and the fourth-biggest selling medicine in 2014, bringing in more than $9bn in sales for Pfizer and Amgen in that year. It is second only to AbbVie's $13bn-a-year Humira (adalimumab) in the anti-TNF market.

Samsung Bioepis - a joint venture between South Korean electronics group Samsung and Biogen - said it plans to launch the product onto its first European markets within the next few weeks. It is already available in South Korea, where it is marketed as Brenzys.

Once launched it will be the second biosimilar anti-TNF drug available in Europe, after Celltrion and Hospira's Inflectra/Remsima, approved last year as the first biosimilar versions of Janssen/MSD's Remicade (infliximab).

It will also be the first biosimilar in the class available as a subcutaneous injection, according to the company, which is also developing biosimilar versions of both Remicade (SB2) and Humira (SB5). All told, the European market for anti-TNF therapies is estimated at around $10bn.

Benepali was granted a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) last November.

"For more than 15 years, anti-TNF therapies have revolutionised the care and outlook for patients living with chronic inflammatory diseases such as RA," said Professor Peter Taylor, a rheumatology specialist based at the University of Oxford.

"However, access to these highly-effective treatments has been restricted by high costs [and] the development of biosimilar drugs is a welcome solution to help alleviate some challenges with access," he added.

Article by
Phil Taylor

18th January 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics